Cargando…

Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma

PURPOSE: For patients with hepatocellular carcinoma awaiting liver transplantation (LT), stereotactic body radiation therapy (SBRT) has emerged as a bridging treatment to ensure patients maintain priority status and eligibility per Milan criteria. In this study, we aimed to determine the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Rashi, Foley, Kimberly, Movahedi, Babak, Masciocchi, Mark J., Bledsoe, Jacob R., Ding, Linda, Rava, Paul, Fitzgerald, Thomas J., Sioshansi, Shirin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897771/
https://www.ncbi.nlm.nih.gov/pubmed/33665482
http://dx.doi.org/10.1016/j.adro.2020.08.016
_version_ 1783653734032605184
author Garg, Rashi
Foley, Kimberly
Movahedi, Babak
Masciocchi, Mark J.
Bledsoe, Jacob R.
Ding, Linda
Rava, Paul
Fitzgerald, Thomas J.
Sioshansi, Shirin
author_facet Garg, Rashi
Foley, Kimberly
Movahedi, Babak
Masciocchi, Mark J.
Bledsoe, Jacob R.
Ding, Linda
Rava, Paul
Fitzgerald, Thomas J.
Sioshansi, Shirin
author_sort Garg, Rashi
collection PubMed
description PURPOSE: For patients with hepatocellular carcinoma awaiting liver transplantation (LT), stereotactic body radiation therapy (SBRT) has emerged as a bridging treatment to ensure patients maintain priority status and eligibility per Milan criteria. In this study, we aimed to determine the efficacy and safety of SBRT in such situations. METHODS AND MATERIALS: A retrospective analysis was conducted of the outcomes of 27 patients treated with SBRT who were listed for LT at 1 institution. Among these, 20 patients with 26 tumors went on to LT and were the focus of this study. Operative reports and postoperative charts were evaluated for potential radiation-related complications. The explant pathology findings were correlated with equivalent dose in 2 Gy fractions and tumor size. RESULTS: Median pretreatment tumor size was 3.05 cm. Median total dose of radiation was 50 Gy delivered in 5 fractions. Pathologic complete response (pCR) was achieved in 16 tumors (62%). Median interval from end of SBRT to transplant was 287 days. Of the 21 tumors imaged before transplant, 16 or 76% demonstrated a clinical complete response based on modified Response Evaluation Criteria in Solid Tumors criteria. There was no significant correlation between pCR rate and increasing tumor size (odds ratio [OR], 0.95; 95% confidence interval, 0.595-1.53) or pCR rate and equivalent dose in 2 Gy fractions (OR, 1.03; 95% confidence interval, 0.984-1.07.) No patients experienced radiation-related operative or postoperative complications. Of the 27 patients who were listed for transplant, the dropout rate was 22%. Two of the 5 patients with Child-Pugh score 10 died of liver failure. CONCLUSIONS: These data demonstrate that SBRT as a bridging modality is a feasible option, with a pCR rate comparable to that of other bridging modalities and no additional radiation-related operative or postoperative complications. There was no dose dependence nor size dependence for pCR rate, which may indicate that for the tumor sizes in this study, the radiation doses delivered were sufficiently high.
format Online
Article
Text
id pubmed-7897771
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78977712021-03-03 Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma Garg, Rashi Foley, Kimberly Movahedi, Babak Masciocchi, Mark J. Bledsoe, Jacob R. Ding, Linda Rava, Paul Fitzgerald, Thomas J. Sioshansi, Shirin Adv Radiat Oncol Clinical Investigation PURPOSE: For patients with hepatocellular carcinoma awaiting liver transplantation (LT), stereotactic body radiation therapy (SBRT) has emerged as a bridging treatment to ensure patients maintain priority status and eligibility per Milan criteria. In this study, we aimed to determine the efficacy and safety of SBRT in such situations. METHODS AND MATERIALS: A retrospective analysis was conducted of the outcomes of 27 patients treated with SBRT who were listed for LT at 1 institution. Among these, 20 patients with 26 tumors went on to LT and were the focus of this study. Operative reports and postoperative charts were evaluated for potential radiation-related complications. The explant pathology findings were correlated with equivalent dose in 2 Gy fractions and tumor size. RESULTS: Median pretreatment tumor size was 3.05 cm. Median total dose of radiation was 50 Gy delivered in 5 fractions. Pathologic complete response (pCR) was achieved in 16 tumors (62%). Median interval from end of SBRT to transplant was 287 days. Of the 21 tumors imaged before transplant, 16 or 76% demonstrated a clinical complete response based on modified Response Evaluation Criteria in Solid Tumors criteria. There was no significant correlation between pCR rate and increasing tumor size (odds ratio [OR], 0.95; 95% confidence interval, 0.595-1.53) or pCR rate and equivalent dose in 2 Gy fractions (OR, 1.03; 95% confidence interval, 0.984-1.07.) No patients experienced radiation-related operative or postoperative complications. Of the 27 patients who were listed for transplant, the dropout rate was 22%. Two of the 5 patients with Child-Pugh score 10 died of liver failure. CONCLUSIONS: These data demonstrate that SBRT as a bridging modality is a feasible option, with a pCR rate comparable to that of other bridging modalities and no additional radiation-related operative or postoperative complications. There was no dose dependence nor size dependence for pCR rate, which may indicate that for the tumor sizes in this study, the radiation doses delivered were sufficiently high. Elsevier 2020-09-14 /pmc/articles/PMC7897771/ /pubmed/33665482 http://dx.doi.org/10.1016/j.adro.2020.08.016 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Investigation
Garg, Rashi
Foley, Kimberly
Movahedi, Babak
Masciocchi, Mark J.
Bledsoe, Jacob R.
Ding, Linda
Rava, Paul
Fitzgerald, Thomas J.
Sioshansi, Shirin
Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma
title Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma
title_full Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma
title_fullStr Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma
title_full_unstemmed Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma
title_short Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma
title_sort outcomes after stereotactic body radiation therapy as a bridging modality to liver transplantation for hepatocellular carcinoma
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897771/
https://www.ncbi.nlm.nih.gov/pubmed/33665482
http://dx.doi.org/10.1016/j.adro.2020.08.016
work_keys_str_mv AT gargrashi outcomesafterstereotacticbodyradiationtherapyasabridgingmodalitytolivertransplantationforhepatocellularcarcinoma
AT foleykimberly outcomesafterstereotacticbodyradiationtherapyasabridgingmodalitytolivertransplantationforhepatocellularcarcinoma
AT movahedibabak outcomesafterstereotacticbodyradiationtherapyasabridgingmodalitytolivertransplantationforhepatocellularcarcinoma
AT masciocchimarkj outcomesafterstereotacticbodyradiationtherapyasabridgingmodalitytolivertransplantationforhepatocellularcarcinoma
AT bledsoejacobr outcomesafterstereotacticbodyradiationtherapyasabridgingmodalitytolivertransplantationforhepatocellularcarcinoma
AT dinglinda outcomesafterstereotacticbodyradiationtherapyasabridgingmodalitytolivertransplantationforhepatocellularcarcinoma
AT ravapaul outcomesafterstereotacticbodyradiationtherapyasabridgingmodalitytolivertransplantationforhepatocellularcarcinoma
AT fitzgeraldthomasj outcomesafterstereotacticbodyradiationtherapyasabridgingmodalitytolivertransplantationforhepatocellularcarcinoma
AT sioshansishirin outcomesafterstereotacticbodyradiationtherapyasabridgingmodalitytolivertransplantationforhepatocellularcarcinoma